2011
DOI: 10.1002/j.2055-2335.2011.tb00675.x
|View full text |Cite
|
Sign up to set email alerts
|

Facilitating Medication Misadventure Risk Assessment in the Emergency Medical Unit

Abstract: Background: The risk of medication misadventure is heightened in emergency settings. Identifying at-risk patients is integral to minimising medication-related adverse events. Aim: To pilot a medication misadventure risk assessment tool to identify at-risk patients most likely to benefit from targeted intervention by an emergency department pharmacist. Method: A prospective descriptive study was undertaken in an emergency medical unit over 2 weeks (June to July 2009). Patients were included if they were over 70… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
12
0

Year Published

2013
2013
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(14 citation statements)
references
References 16 publications
2
12
0
Order By: Relevance
“…Although beneficial, there is less opportunity with this model of care for the EM pharmacist to contribute to early time‐critical review of undifferentiated patients before admission, potentially preventing errors before they occur. Understanding which patients to prioritise is an ongoing area of research …”
Section: Discussionmentioning
confidence: 99%
“…Although beneficial, there is less opportunity with this model of care for the EM pharmacist to contribute to early time‐critical review of undifferentiated patients before admission, potentially preventing errors before they occur. Understanding which patients to prioritise is an ongoing area of research …”
Section: Discussionmentioning
confidence: 99%
“…A number of studies have been conducted by its members, which have benefited many and provided much needed clinical and practical evidence used by EM pharmacists and their managers across the country . The most recent of these will build on previous work and help answer the age‐old problem faced by EM pharmacists: how should EM pharmacists prioritise patients to be seen in the ED? This has followed the model used by other professional groups to answer questions and enhance learning by harnessing peers at many hospital sites in different states for the greater good (e.g. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials group and, more recently, the model to be used by the SHPA National Translational Research Collaborative (NTRC) launched in 2017).…”
Section: Conflict Of Interests Statementmentioning
confidence: 99%
“…EM pharmacists may focus on patients being discharged from the ED who will not have another opportunity for hospital pharmacist review on the wards. A pilot study undertaken in a major metropolitan ED, with approximately 200 presentations daily, identified 40 patients presenting each day who would meet the Kumar criteria for being seen by a pharmacist. Anecdotally, often established EM pharmacy services will see approximately 10–15 patients per 8‐h shift with the equivalent of one full‐time pharmacist.…”
Section: Extent and Operationmentioning
confidence: 99%
“…The quality assurance program should demonstrate that the EM pharmacy service is targeting and achieving optimal outcomes for patient groups at greatest risk for medicine misadventure. As limited work has been done to develop and validate the medicine misadventure risk‐screening tools, further work should focus on development and validation of robust, broadly applicable screening tools.…”
Section: Qualitymentioning
confidence: 99%